SG11202113187WA - Modified adenoviruses - Google Patents

Modified adenoviruses

Info

Publication number
SG11202113187WA
SG11202113187WA SG11202113187WA SG11202113187WA SG11202113187WA SG 11202113187W A SG11202113187W A SG 11202113187WA SG 11202113187W A SG11202113187W A SG 11202113187WA SG 11202113187W A SG11202113187W A SG 11202113187WA SG 11202113187W A SG11202113187W A SG 11202113187WA
Authority
SG
Singapore
Prior art keywords
modified adenoviruses
adenoviruses
modified
Prior art date
Application number
SG11202113187WA
Other languages
English (en)
Inventor
Karin Jooss
Ciaran Scallan
Leonid Gitlin
Original Assignee
Gritstone Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Bio Inc filed Critical Gritstone Bio Inc
Publication of SG11202113187WA publication Critical patent/SG11202113187WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202113187WA 2019-05-30 2020-06-01 Modified adenoviruses SG11202113187WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854865P 2019-05-30 2019-05-30
PCT/US2020/035591 WO2020243719A1 (en) 2019-05-30 2020-06-01 Modified adenoviruses

Publications (1)

Publication Number Publication Date
SG11202113187WA true SG11202113187WA (en) 2021-12-30

Family

ID=73553330

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113187WA SG11202113187WA (en) 2019-05-30 2020-06-01 Modified adenoviruses

Country Status (13)

Country Link
US (2) US11591619B2 (he)
EP (1) EP3976075A4 (he)
JP (2) JP7457733B2 (he)
KR (1) KR20220016137A (he)
CN (1) CN114072516A (he)
AU (1) AU2020282369A1 (he)
BR (2) BR122024002387A2 (he)
CA (1) CA3140019A1 (he)
IL (1) IL288283A (he)
MX (1) MX2021014525A (he)
SG (1) SG11202113187WA (he)
TW (1) TW202110870A (he)
WO (1) WO2020243719A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021119545A1 (en) * 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
RU2743963C1 (ru) * 2021-02-09 2021-03-01 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Средство для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 в жидкой форме (варианты)
RU2743962C1 (ru) * 2021-02-10 2021-03-01 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Средство для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 в лиофилизированной форме (варианты)
WO2023069551A1 (en) * 2021-10-20 2023-04-27 The Regents Of The University Of California Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes
CN114410689B (zh) * 2022-03-29 2022-06-17 北京循生生物医学研究有限公司 一种增强肿瘤浸润淋巴细胞杀伤力的制备方法

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
EP0982405B1 (en) 1993-09-15 2009-08-26 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5837484A (en) 1993-11-09 1998-11-17 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US6001557A (en) 1994-10-28 1999-12-14 The Trustees Of The University Of Pennsylvania Adenovirus and methods of use thereof
US5552350A (en) 1994-12-12 1996-09-03 Ceramco Inc. Low-fusing temperature porcelain
NZ300387A (en) * 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5851796A (en) * 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
EP0910343A1 (en) 1996-07-03 1999-04-28 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
PT1199368E (pt) 1998-07-07 2004-04-30 Transgene Sa Utilizacao de blocos de leitura da regiao e4 adenoviral para melhorar a expressao de um gene relevante
EP1000628A1 (en) 1998-09-28 2000-05-17 Fondation Mondiale Recherche et Prevention SIDA Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
EP1137759A2 (en) 1998-12-07 2001-10-04 U.S. Medical Research Institute of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine
WO2000047229A2 (en) 1999-02-11 2000-08-17 Genzyme Corporation Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
ES2300261T3 (es) 1999-04-08 2008-06-16 Novartis Vaccines And Diagnostics, Inc. Potenciacion de la respuesta inmune para aplicaciones de vacunas y terapia genetica.
EP1175497B1 (en) 1999-04-14 2010-04-07 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
EP1244465A4 (en) 1999-12-21 2005-01-12 Epimmune Inc INDUCTION OF CELLULAR IMMUNE RESPONSE TO PROSTATE CANCER BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
EP2311950A1 (en) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
AU2001252945A1 (en) 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20040115625A1 (en) 2000-10-02 2004-06-17 Reinhard Ebner Cancer gene determination and therapeutic screening using signature gene sets
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001291162A1 (en) 2000-09-25 2002-04-08 Regents Of The University Of Michigan Production of viral vectors
US20020137081A1 (en) 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
EP1363660A4 (en) 2001-02-01 2006-06-21 Univ Johns Hopkins HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
CN1147587C (zh) * 2001-05-30 2004-04-28 方炳良 一种增强细胞特异性目的基因表达的方法
EP1399183B1 (en) 2001-05-31 2010-06-30 Novartis Vaccines and Diagnostics, Inc. Chimeric alphavirus replicon particles
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
IL164802A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003287019B2 (en) 2002-10-03 2010-07-22 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
US7078218B2 (en) 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
DK1585812T3 (en) 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
GB2398300A (en) 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
MXPA05012542A (es) 2003-06-05 2006-02-08 Wyeth Corp Composiciones inmunogenicas que comprenden vectores de replicon del virus de la encefalitis equina venezolana y antigenos de la proteina del paramixovirus.
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
PL2163260T3 (pl) 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
US8394386B2 (en) * 2004-04-28 2013-03-12 The Trustees Of The University Of Pennsylvania Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
WO2006033672A2 (en) * 2004-04-28 2006-03-30 The Trustees Of The University Of Pennsylvania Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
US9024001B2 (en) 2004-05-25 2015-05-05 Novartis Vaccines And Diagnostics, Inc. Alphavirus replicon packaging constructs
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
ES2310848T3 (es) 2004-10-04 2009-01-16 Biovaxim Limited Vacunas de virus enteros inactivados correspondientes a un subtipo para tratar pacientes con la infeccion vih.
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
FR2882557A1 (fr) 2005-02-25 2006-09-01 Centre Nat Rech Scient Epitopes de vih et composition pharmaceutique les contenant
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
PL2002003T3 (pl) * 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
ES2735531T3 (es) 2005-08-23 2019-12-19 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
WO2007098267A2 (en) 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
AU2007296489B2 (en) 2006-09-12 2013-07-04 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8969542B2 (en) 2007-05-31 2015-03-03 Genimmune N.V. HPV polyepitope constructs and uses thereof
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US20100015179A1 (en) 2007-08-16 2010-01-21 Frolov Ilya V Attenuation of encephalitogenic alphavirus and uses thereof
EP2201023A2 (en) 2007-09-14 2010-06-30 GENimmune N.V. Affinity tag
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US9234181B2 (en) 2007-11-26 2016-01-12 Novartis Ag RNA expression cassette and cells for making alphavirus particles
WO2009092113A2 (en) 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
US20090253184A1 (en) 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
KR101913790B1 (ko) 2008-01-24 2018-12-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
JP2011517409A (ja) 2008-03-28 2011-06-09 バイレクシス コーポレイション レンチウイルスベースの免疫原性ベクター
CA2726914A1 (en) 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
US8093021B2 (en) 2008-06-13 2012-01-10 New York University Defective sindbis viral vectors
ES2544702T3 (es) 2008-07-17 2015-09-02 Medigen, Inc. Vacunas en forma de ADNi y métodos para utilizarlas
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8807362B2 (en) 2008-10-17 2014-08-19 Jeong-min Lee Bottle cap
EP3613761A1 (en) 2008-11-26 2020-02-26 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
CA3108979A1 (en) * 2009-02-02 2010-08-05 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN101579528B (zh) 2009-06-24 2011-06-29 中国人民解放军军事医学科学院军事兽医研究所 一种hiv复合多表位dna疫苗及其应用
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
WO2011082388A2 (en) 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
BR112013000391B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição de emulsão catiônica de óleo em água e seu uso
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
WO2012006376A2 (en) 2010-07-06 2012-01-12 Novartis Ag Virion-like delivery particles for self-replicating rna molecules
KR101667094B1 (ko) 2010-08-16 2016-10-17 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 항암 아데노바이러스
HUE061275T2 (hu) 2010-08-31 2023-06-28 Glaxosmithkline Biologicals Sa Kis liposzómák immunogént kódoló RNS bejuttatására
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
RS63983B1 (sr) 2010-08-31 2023-03-31 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
KR20190100425A (ko) 2010-12-30 2019-08-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
HUE057608T2 (hu) 2011-05-24 2022-06-28 BioNTech SE Individualizált vakcinák a rák ellen
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP4115876A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
US8859507B2 (en) 2011-08-16 2014-10-14 Samsung Electronics Co., Ltd. Protein complex for intracellular delivery and uses thereof
TR201900264T4 (tr) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
RU2014118727A (ru) 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
RU2705301C2 (ru) 2012-02-16 2019-11-06 Влп Терапьютикс, Ллк Композиция вирусоподобных частиц
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
WO2013173702A2 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US10240128B2 (en) 2012-07-04 2019-03-26 Sirion Biotech Gmbh Means and methods to increase adenovirus production
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
GB201220119D0 (en) 2012-11-08 2012-12-26 Univ Cork Vector
EP2920313B1 (en) 2012-11-16 2019-06-12 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
KR101429696B1 (ko) * 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
US9402888B2 (en) 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
KR102341899B1 (ko) 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
IL242656B (he) 2013-06-03 2022-07-01 Vlp Therapeutics Inc חיסון למלריה
PE20171142A1 (es) * 2013-11-01 2017-08-10 Pfizer Vectores para expresion de antigenos asociados a prostata
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
ES2921531T3 (es) 2013-12-06 2022-08-29 Broad Inst Inc Formulaciones para vacunas contra la neoplasia
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
JP2017527564A (ja) 2014-09-03 2017-09-21 バヴァリアン ノルディック エー／エス 免疫応答の増進を目的とする方法及び組成物
JP6863893B2 (ja) 2014-11-26 2021-04-21 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
CN107405393A (zh) 2015-01-29 2017-11-28 新加坡科技研究局 携带基孔肯亚相关肽的纳米胶囊
DK3253795T3 (da) 2015-02-06 2019-07-29 Navigo Proteins Gmbh Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter
WO2016154047A2 (en) 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
CA2980292A1 (en) 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
HUE055458T2 (hu) 2015-09-21 2021-11-29 Trilink Biotechnologies Llc Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére
EP3936154A1 (en) 2015-10-12 2022-01-12 NantOmics, LLC Compositions and methods for viral cancer neoepitopes
IL259931B2 (he) 2015-12-16 2024-02-01 Gritstone Bio Inc זיהוי נאו–אנטיגנים, הכנה, ושימוש
WO2017151524A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods and systems for evaluating tumor mutational burden
KR20180132070A (ko) 2016-03-03 2018-12-11 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US20190307868A1 (en) 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2017192924A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
WO2017208191A1 (en) 2016-06-02 2017-12-07 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
MY189551A (en) 2016-06-20 2022-02-16 Isa Pharmaceuticals B V Formulation of a peptide vaccine
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
CN107698593A (zh) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
EP3500294A4 (en) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation ANTI-PD-1 ANTIBODIES OR FRAGMENTS THEREOF FOR TREATING HEPATITIS B
BR112019010565A2 (pt) 2016-11-23 2019-09-17 Gritstone Oncology Inc aplicação viral de neoantígenos
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
BR112019010275A2 (pt) 2016-12-09 2019-09-17 Glaxosmithkline Biologicals Sa adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201621732D0 (en) 2016-12-20 2017-02-01 Agricultural Research Council A multi-epitope dna vaccine for heartwater
JP7325327B2 (ja) 2016-12-21 2023-08-14 アルブータス・バイオファーマー・コーポレイション インフュージョンリアクションを改善するための方法
CN108064305B (zh) * 2017-03-24 2021-10-08 清华大学 可编程的溶瘤病毒疫苗系统及其应用
US20230241207A1 (en) 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
JP2020523010A (ja) 2017-06-09 2020-08-06 グリットストーン オンコロジー インコーポレイテッド 新生抗原の特定、製造、及び使用
WO2018232330A1 (en) 2017-06-16 2018-12-20 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b
CN111492245A (zh) 2017-07-21 2020-08-04 基因泰克公司 癌症的治疗和诊断方法
KR20200115450A (ko) 2017-08-07 2020-10-07 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
WO2019090156A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
EP3762512A1 (en) 2018-03-06 2021-01-13 Cancer Research Technology Limited Improvements in variant detection
CA3099642A1 (en) 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Immune checkpoint inhibitor co-expression vectors
TW202000907A (zh) 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 共有抗原
US20220125919A1 (en) 2018-11-07 2022-04-28 Gritstone Bio, Inc. Alphavirus neoantigen vectors and interferon inhibitors
EP3993829A4 (en) 2019-07-02 2024-01-03 Gritstone bio, Inc. HIV ANTIGENS AND MHC COMPLEXES
WO2021092095A1 (en) 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Neoantigen vaccine therapy
WO2021119545A1 (en) 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
EP4087940A4 (en) 2020-01-10 2024-04-10 Gritstone bio, Inc. CELLULAR DNA MONITORING
AU2021258191A1 (en) 2020-04-21 2022-12-01 Gritstone Bio, Inc. Antigen-encoding cassettes
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes

Also Published As

Publication number Publication date
US11591619B2 (en) 2023-02-28
BR112021024127A2 (pt) 2022-04-26
KR20220016137A (ko) 2022-02-08
TW202110870A (zh) 2021-03-16
US20220090138A1 (en) 2022-03-24
IL288283A (he) 2022-01-01
BR122024002387A2 (pt) 2024-03-12
US20230407332A1 (en) 2023-12-21
AU2020282369A1 (en) 2022-01-20
JP2024073576A (ja) 2024-05-29
JP2022534282A (ja) 2022-07-28
EP3976075A4 (en) 2023-08-16
CA3140019A1 (en) 2020-12-03
EP3976075A1 (en) 2022-04-06
CN114072516A (zh) 2022-02-18
WO2020243719A1 (en) 2020-12-03
JP7457733B2 (ja) 2024-03-28
MX2021014525A (es) 2022-03-17

Similar Documents

Publication Publication Date Title
DK3958977T3 (en) Camptothecinderivater
CA196372S (en) Soundbar
IL288283A (he) נגיף אדנו שעבר שינוי
IL276535A (he) אדנווירוסים מותאמים
ZA202005848B (en) Modified oncolytic adenoviruses
CA191618S (en) Floorwasher - nozzle
CA201154S (en) Banquette
GB201901778D0 (en) Aladin
DK3980417T3 (en) PRMT5-Inhibitorer
CA190552S (en) Hand-dryer
CA189677S (en) Uroflowmeter
CA193248S (en) Mandoline
CA190384S (en) Beverageware
CA190385S (en) Beverageware
EP3689729C0 (en) NON-SLIP PEDAL
CA189047S (en) Hammock-tent
CA194482S (en) Kick-scooter
CA195219S (en) Overall
DK3832828T3 (en) Strømforyningsnetsystem
CA192228S (en) Hydrogenerator
CA190974S (en) Hoodie
CA190387S (en) Beverageware
CA190386S (en) Beverageware
CA189434S (en) Jerrycan
CA187366S (en) Hoodie